Oncology Imaging - Tumour Response Assessment with RECIST and Beyond is organized by Unilabs Academy and will be held from Sep 15 - 17, 2027.
Schedule: 13:30–17:00 CEST (UTC+2), online via Zoom.
Description:
The purpose of this cancer imaging fellowship is to provide a comprehensive overview of imaging criteria (RECIST 1.1 in particular) to assess tumour response in patients receiving systemic therapy. RECIST 1.1 criteria are widely used in clinical trials comparing the efficacy of several therapeutic strategies.
Response Evaluation Criteria in Solid Tumors (RECIST) is a set of standardized guidelines for assessing treatment response in solid tumours.
A thorough understanding of these criteria principles and subtleties is important for radiologists involved in clinical trials. Outside clinical trials, RECIST 1.1 can also be used for more comfortable interpretation of images, with structured reporting, to better communicate with oncologists. With the arrival of new, more targeted treatments in oncology, the RECIST criteria had to be adapted and new criteria developed, such as iRECIST for immunotherapy.
Each module starts with a lecture. After the lecture, you will be challenged to practise on key clinical cases. After and during the individual case readings there will be plenty of time for group discussion and Q&A with Dr. Caramella.
Learning Objectives
Programme will include
Level
Level II - General radiologist
This cancer imaging fellowship is ideal for radiologists involved in oncologic imaging who want to learn more how to handle tumoral evaluation in any situation.
A RECIST criteria course would be of interest to a variety of healthcare professionals and researchers involved in oncology, including medical, surgical, and radiation oncologists who need to assess and monitor the effectiveness of cancer treatments in their patients.
CME accreditation pending submission for the 2027 fellowship.
Copyrights © 2026 eMedEvents Corporation, All Rights Reserved